Crossmark

Enhancing cannabinoid bioavailability: a crossover study comparing a novel self-nanoemulsifying drug delivery system and a commercial oil-based formulation

Crossref DOI link: https://doi.org/10.1186/s42238-025-00294-8

Published Online: 2025-06-13

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hermush, Vered

Mizrahi, Nisim

Brodezky, Tal

Ezra, Rafael
License Information

Text and Data Mining valid from 2025-06-13

Version of Record valid from 2025-06-13
More Information

Article History

Received: 25 February 2025

Accepted: 8 June 2025

First Online: 13 June 2025

Declarations

:

: This study was conducted in accordance with the guidelines of the Declaration of Helsinki and Good Clinical Practice. The trial, registered at ClinicalTrials.gov under identifier NCT06149988, was approved by the Laniado Hospital Ethics Committee (project LND-0023-22) and the clinical trials department at the Israel Ministry of Health (project 202227779).

: R.E. is the CEO of Capsoil Technologies Ltd., the company that funded this study. However, R.E. was not involved in the data collection, data analysis, data interpretation, or the writing of the manuscript. All other authors declare that they have no competing interests.

: All individual participants involved in the study provided informed consent prior to their participation. Written informed consent was obtained from each participant to ensure compliance with ethical research guidelines.

Document is current

Any future updates will be listed below